Weber, Philipp Autor ID: 3652559 ver autor

Articulos ( 13 en total, se muestran 3 )

● A dusty filament and turbulent CO spirals in HD 135344B-SAO 206462, 2021

● A multiwavelength analysis of the spiral arms in the protoplanetary disk around WaOph 6, 2021

● Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FU Orionis, 2024

Afiliaciones ( 5 en total, se muestran 3 )

● Millennium Nucleus Young Exoplanets & their Moons

● Núcleo Milenio sobre Exoplanetas Jóvenes y sus Lunas

● Núcleo Milenio sobre Exoplanetas Jóvenes y sus Lunas

Weber, P. E. Y. Autor ID: 5960981 ver autor

Articulos ( 4 en total, se muestran 3 )

● First-line lenvatinib (Len) plus pembrolizumab (Pembro) plus chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in, 2022

● Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study, 2023

● Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study, 2023

Afiliaciones ( 1 en total )

● Universidad de La Frontera

Weber, P. Autor ID: 6272348 ver autor

Articulos ( 4 en total, se muestran 3 )

● Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer, 2023

● Immune Infiltrates Associated with Tumor Budding in Gastric Adenocarcinoma: A Histopathological Characterization, 2020

● Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer, 2021

Afiliaciones ( 1 en total )

● Universidad de La Frontera

Weber, P. Yanez Autor ID: 6931389 ver autor

Articulos ( 1 en total )

● Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, 2023

Afiliaciones ( 1 en total )

● Universidad de La Frontera

Weber Salazar, Pia Autor ID: 7575478 ver autor

Articulos ( 1 en total )

● Towards durable legal protections for rivers in Chile, 2024

Afiliaciones ( 2 en total )

● Pew Charitable Trust

● The Pew Charitable Trust

Weber, P. E. Yanez Autor ID: 7970620 ver autor

Articulos ( 1 en total )

● Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer, 2024

Afiliaciones ( 1 en total )

● James Lind Ctr Invest Canc

Weber, Philipp Autor ID: 8248099 ver autor

Articulos ( 1 en total )

● High-resolution ALMA observations of V4046 Sgr: a circumbinary disc with a thin ring, 2022

Afiliaciones ( 2 en total )

● Universidad de Chile

● Universidad de Santiago de Chile

Weber, P. E. Yanez Autor ID: 8282092 ver autor

Articulos ( 1 en total )

● KEYNOTE-859 update: Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer, 2024

Afiliaciones ( 1 en total )

● Universidad de La Frontera

Weber, P. E. Yanez Autor ID: 8331109 ver autor

Articulos ( 1 en total )

● Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma, 2024

Afiliaciones ( 1 en total )

● Universidad de La Frontera

Weber, P. E. Yanez Autor ID: 8348965 ver autor

Articulos ( 1 en total )

● Neoadjuvant and adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study, 2024

Afiliaciones ( 1 en total )

● Universidad de La Frontera

Weber, P. E. Yanez Autor ID: 8349876 ver autor

Articulos ( 1 en total )

● Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma, 2024

Afiliaciones ( 1 en total )

● Clin Alemana Temuco SA